BioSpace News Archive

Shanghai Henlius Biotech, Inc. announced that the United States Food and Drug Administration has granted Orphan-Drug Designation for HANSIZHUANG for the treatment of small cell lung cancer.

Viracta Therapeutics, Inc. announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT.

Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for LeukoPrint® Molecular Karyotyping Kit and is now ready to launch this test in European markets.

Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).

The ‘717 patent provides broad protection for Defence’s extremely versatile vaccine platform that can be incorporated into virtually any cell-based or protein subunit vaccine to enhance immunogenicity.

The aim of PharmaDrug’s DMT-analogue research program in ocular health is to develop suitable prototype medical devices capable of sustained ocular drug-delivery while also confirming efficacy, biocompatibility and stability of its candidate molecules in models of elevated IOP.

Essent Biologics™, a leading supplier of adult human-derived cell and scaffold materials, today announced it has launched a new line of primary cells: Wharton’s jelly-derived Mesenchymal Stromal Cells (hWJMSC), to its growing product portfolio.

Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry, announced that it will open two new drug discovery and development facilities to support its ongoing efforts to advance novel small molecule drugs.

NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to commence the largest trial of external Trigeminal Nerve Stimulation (eTNS) ever conducted.